ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ARGX Argen X SE

339.30
-2.70 (-0.79%)
Last Updated: 21:15:30
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Argen X SE ARGX Euronext Ordinary Share
  Price Change Price Change % Share Price Last Trade
-2.70 -0.79% 339.30 21:15:30
Open Price Low Price High Price Close Price Previous Close
338.00 335.10 340.00 342.00
more quote information »

Recent News

Date Time Source Heading
16/4/202415:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/3/202417:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
27/3/202407:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/3/202417:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
08/3/202408:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29/2/202417:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/2/202417:00GLOBEargenx to Present at Upcoming Investor Conferences
22/2/202417:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/2/202417:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/1/202417:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/1/202417:00GLOBEargenx Highlights 2024 Strategic Priorities
02/1/202417:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20/12/202317:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28/11/202317:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
16/11/202323:40GLOBEargenx Announces European Commission Approval of..
01/11/202317:00GLOBEargenx Highlights Data Evaluating VYVGART in Neuromuscular..
31/10/202317:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202316:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
21/9/202315:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/9/202315:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/8/202315:00GLOBEargenx to Present at Upcoming Investor Conferences
27/7/202315:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
25/7/202306:30GLOBEargenx announces closing of global offering
20/7/202315:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
20/7/202307:58GLOBEargenx announces full exercise of underwriters’ option to..
19/7/202311:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
18/7/202306:01GLOBEargenx announces launch of proposed global offering
17/7/202315:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
30/6/202323:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
21/6/202308:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
20/6/202315:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
31/5/202315:00GLOBEargenx to Present at Upcoming Investor Conferences
04/5/202315:00GLOBEargenx Reports First Quarter 2023 Financial Results and..
04/5/202306:01GLOBEargenx announces results of Annual General Meeting of..
02/5/202315:00GLOBEargenx to Present at BofA Securities 2023 Health Care..
27/4/202315:00GLOBEargenx to Report First Quarter 2023 Financial Results and..

Your Recent History

Delayed Upgrade Clock